Pharmaceutical

Maravai LifeSciences Announces November 2024 Investor Conference Schedule

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents…

2 months ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025INDIANAPOLIS and FLORHAM PARK, N.J.,…

2 months ago

Nkarta to Participate in an Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural…

2 months ago

Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)  

MORRISTOWN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today…

2 months ago

Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer

BOSTON and SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing…

2 months ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also showcase the…

2 months ago

Transpire Bio Announces Corporate Office Expansion

WESTON, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics…

2 months ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial…

2 months ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract…

2 months ago

Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect…

2 months ago